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Abstract
Background: The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously
showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate
to severe disease. The morbidity associated with this disease is known to have serious negative
impact on the overall quality of life(QOL) of affected individuals.
Methods: The data in this report were collected from the 299 patients enrolled in the MSH.
Health quality of llife (HQOL) measures were assessed in the MSH as a secondary endpoint to
determine if the clinical benefit of HU could translate into a measurable benefit perceptible to the
patients. HQOL was assessed with the Profile of Mood States, the Health Status Short Form 36
(SF-36), including 4-week pain recall, and the Ladder of Life, self-administered twice 2-weeks apart
pre-treatment and every 6 months during the two-year, randomized, double-blind, treatment
phase. The effects of factors including randomized treatment, age, gender, pre-treatment crises
frequency, Hb-F level mean, daily pain from 4-week pre-treatment diaries, and 2-year Hb-F
response level (low or high) were investigated.
Results: Over two years of treatment, the benefit of HU treatment on QOL, other than pain
scales, was limited to those patients taking HU who maintained a high HbF response, compared to
those with low HbF response or on placebo. These restricted benefits occurred in social function,
pain recall and general health perception. Stratification according to average daily pain prior to
treatment showed that responders to HU whose average daily pain score was 5–9 (substantial pain)
achieved significant reduction in the tension scale compared to the placebo group and to nonresponders. HU had no apparent effect on other QOL measures.
Conclusion: Treatment of SS with HU improves some aspects of QOL in adult patients who
already suffer from moderate-to-severe SS.
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Background
Health-related quality of life (HQOL) is a multidimensional concept that includes the physical, emotional, and
psychosocial components associated with a disease or its
treatment [1] in different domains of life [2-4], addressing
the patients' perceptions of their situations [2-4]. Increasing self-reported satisfaction in the domains of life is associated with higher levels of quality of life. Improving
HQOL has become an important objective of medical care
[2-4]. It is the goal of health care providers to enhance
treatment outcome and restore comfort and well being to
the lives of their patients. Achievement of this goal, however, is a function of the disease process that is being
treated. Thus, improving the HQOL of patients with
chronic disease and of patients with chronic pain is a challenge.
Acute episodes of pain are the principal symptom of sickle
cell disease (SCD). In the Cooperative Study of Sickle Cell
Disease (CSSCD), an analysis of painful crises in 3,578
patients ranging in age from newborns to age 66 [5-7]
conducted from 1982–1995, the average crisis rate was 0.8
episodes per patient-year in SS, 1.0 episode per patientyear in sickle β0-thalassemia and 0.4 episodes per patientyear in SC and sickle β+-thalassemia. The rates varied
widely within each of these 4 groups: 39% of patients with
sickle cell anemia had no episodes of pain, and 1% had
more than 6 episodes per year. The 5.2% of CSSCD
patients with 3 to 10 episodes per year had 32.9% of all
episodes. Among CSSCD patients over the age of 20, those
with high crisis rates had higher mortality levels than
those with low crisis rates. High crisis rates were associated with high hematocrit and low fetal hemoglobin levels. Fetal hemoglobin level was predictive of the crisis rate,
suggesting that attempts to increase the fetal hemoglobin
level with pharmacological agents such as hydroxyurea
might decrease the crisis rate and ultimately improve survival. CSSCD data suggest that sickle cell disease can have
an impact on the patient's ability to complete education,
develop work skills and hold full-time employment. SCD
can influence social and family adjustment also.
The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Trial was a randomized, double-blind, placebo (PL)-controlled trial conducted in 299 SS patients
with 3 or more annual crises at 21 clinical centers [8,9].
Daily oral hydroxyurea reduced painful sickle cell episodes, hospitalizations for painful episodes, acute chest
syndrome and total number of units of blood transfused.
Although patients with sickle cell anemia (SS) have been
treated with opioid and non-opioid analgesics routinely
in an effort to decrease their pain and suffering, there has
been little information on the effect on QOL from controlled trials to reduce pain in this patient population.

http://www.hqlo.com/content/4/1/59

As part of the MSH, demographic and quality of life measures were obtained from all study subjects to assess the
impact of hydroxyurea therapy on the patients' perception
of pain, stamina and the day-to-day activities of living. We
report on the effect of treatment of SS anemia on QOL.
This is a secondary endpoint analysis for randomized
treatment with hydroxyurea.

Methods
The patients included in this report are the 277 of the 299
enrolled in the Multicenter Study of Hydroxyurea in Sickle
Cell Anemia (MSH) [8,9] conducted from 1992 to 1995.
Daily oral HU was titrated to maximum doses that did not
cause unacceptable marrow depression over an average
2.4 years after randomization. The health related quality
of life measures (QOL) collected twice 2 weeks apart pretreatment (the mean was used as the baseline value) and
every 6 months up to 2 years of randomized treatment
were the MOS Health Status Survey Short Form (SF-36),
the Profile of Mood Status (POMS) and the ladder of life
[10-13]. Use of the MOS Short Form 36 General Health
Survey was by courtesy of the Medical Outcomes Institute.
Patients completed diaries of daily bodily pain rated on a
10-step scale with 0 = no pain and 9 = worst imaginable
pain. Mean daily pain was computed over the 28 days pretreatment a covariate for analysis.
Patients gave signed informed consent for participation in
the randomized trial.
Health Status Survey (SF-36) results were scored according
to the manual [11]; scores were converted to a 0–100%
scale for ready comparison with results from other populations with 0 signifying the worst and 100 the best; for
the SF-36 pain recall (distinct from the pain diary measure), 0 signified greatest pain (also worst) and 100, least
pain. The domains measured with the Profile of Mood
States were Tension-Anxiety and Depression-Dejection in
which lower scores indicate lower tension or depression,
i.e., better state, and Vigor and Fatigue in which lower
scores indicate worse state (less vigor or more fatigue,
respectively). The ladder of life is a subjective 10-step scale
from "the best life for you" (level 10) to "the worst possible life for you" (level 1).
Only those patients with a 2-year Hb-F response (N =
277) were included in the analysis.). Of the remaining 22
patients, 6 had died by 2 years and the remaining 16 were
no longer returning for clinic visits or did not give provide
blood specimens for HbF determination (145). Of the
277, those missing a small number of HQOL data points
during the 2-year follow-up comprised 1 additional HU
who died, 3 HU patients lost to follow-up and 2 PL
patients lost to follow-up. Death and loss to follow-up in
the first 2 years resulted in HQOL data missing at random.
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Statistical methods
Health-related quality of life (HQOL) results for the MSH
patients are presented as mean scores and standard errors
in the Appendix tables and as mean ± 99% confidence
interval in the figures, over time, according to HU- or PLassigned randomized treatment, or grouped according to
assigned treatment and HbF response at two years [14].
Differences between randomized groups (i.e., intentionto-treat analyses) and between post-hoc groups (i.e., high
HbF responders vs. low responders by two years and placebo) are tested with generalized estimating equations
models (GEE), which account for multiple (serial) observations per patient and consequent auto-correlation.
Models were constructed starting with univariate models
testing for the effects of treatment group assignment on
the change from baseline to 6, 12, 18 and 24 months of
each outcome measure. This initial model was expanded
in a step-wise fashion to include other characteristics
related to outcomes of the treatment that could potentially be related to QOL. Interaction tests were performed
before combining first-order terms in more comprehensive models. Characteristics tested univariately first for
their effect on QOL outcomes included pre-treatment
QOL measures, gender, age, average daily pain from
patient diaries, pre-treatment rate of acute vaso-occlusive
(painful) crisis (<6/yr or ≥ 6/yr) and pre-treatment HbF
(<0.5 g/dL or ≥ 0.5 g/dL). These factors were then
included together with initial treatment assignment or
HbF response in higher-order, multiply adjusted models.

Because of multiple testing, and the fact that QOL measures are considered secondary end points in the trial, the
strength of statistical evidence for differences between
groups was pre-determined at a more stringent level than
the overall trial design of α = 0.05. The trial was not
designed to detect specified differences in secondary
measures a priori. Thus, observed differences carrying a
nominal p-value of <0.01 are considered indicative of a
possible difference, and those with a p-value of <0.001 are
considered to provide stronger evidence of a difference.

Results
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Selected parameters from MOS Short-Form SF-36 Health
Quality of Life and the Profile of Mood States in adults with
moderate-severe sickle cell anemia, treated with hydroxyurea (solid line) or placebo (dashed line) for two years. Mean
quality of life measures and the standard error of the mean
are shown.

Of the 299 MSH patients, 49% were male and 51%
female. Their age distribution at trial entry was as follows:
18–29 (51%), 30–39 (39%), 40–49 (9%), >=50 (1%).
Fifty-six percent had 6 or more crises annually (Fig 1A)
and 44% reported mean daily pain of 4 or more on a scale
of 0–9 (Fig 1B). The baseline HQOL results of the total
MSH patient population were compared to published
results including the Medical Outcomes Study [2], reference groups and a prospective cohort of sickle cell patients
[15] followed at the Medical College of Georgia (MCG)
1985–1995 (Table 1). Both groups of sickle cell patients
(MCG and MSH) had lower SF-36 scores on all measures,
compared with a large reference group with no chronic
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Table 1: Comparison of MSH patients and other reference patient groups on SF-36 Measures

Patient Group

No Chronic Conditions* (N = 2595)
Myocardial Infarction* N = 147
Arthritis* N = 2079
Sickle Cell Anemia † N = 143
MSH** N = 299

Physical
Functioning
86.0
64.6
81.1
63.6
66.0

Health Status Short Form 36 Scores
Role-Physical
Social
Mental
Health
Functioning
Health
Perception
87.2
58.6
76.9
45.3
46.7

92.3
80.7
88.4
65.1
6.65.0

77.6
74.8
74.6
70.0
70.0

72.6
62.7
65.3
42.4
38.8

Bodily Pain
Recall
74.2
71.7
58.6
44.8
46.5

*Data from Stewart et. al (2), † Data from Woods et. al (15), ** MSH: Multicenter Study of Hydroxyurea in Sickle Cell Anemia

conditions. MSH patients were quite comparable to the
MCG sickle cell patients in all six measures that could be
compared from the SF-36. They scored considerably worse
than the reference group with the lowest SF-36 scores,
namely patients with myocardial infarction, and also
worse than the reference group with chronic pain, namely
arthritis.
Baseline QOL results were available on all 299 MSH
patients according to originally assigned treatment group.
In two years of follow-up, there were a few losses of
patients to death (n = 8) and inability to complete followup visits (n = 16). Fig. 1 shows the mean ± 3 × SE of the
HQOL measures according to original treatment group
assignment and time (pre-treatment and every six months
for two years of the trial). The data shown in Figs. 2 and 3
are listed in Tables A and B of the Appendix.
Analysis of daily pain and frequency of pain episodes
show that these subjects were severely affected by sickle
cell disease at study entry (Fig. 1). Mean daily pain on a 0to-9 scale self-reported for four weeks pre-treatment, was
distributed as follows: 7% reported zero mean daily pain,
49% reported pain averaging 1–3, 35% had average pain
4–6 and 9% reported average daily pain of 7–9 (Fig. 3A).
Pre-treatment annual crisis rates were distributed as follows: 44% had 3–5 annual crises, 24% had 6–9 and 32%
had 10 or more (Fig 1B).

assigned patients with a high two-year response to HbF
scored significantly better in "general health now" (p <
0.001), four-week pain recall (p = 0.004) and general
health perception (p = 0.001) compared to those with low
two-year HbF response or placebo (Fig 2 and Appendix
Table B). A regression model of the effect of high HbF
response on QOL adjusting for baseline values of QOL
measures, HbF, annual crisis rate and mean daily pain are
shown in Table 2. The baseline value of each QOL outcome was always predictive of the outcome at follow-up.
The results of the model for each QOL outcome (columns) magnified the effect of high HbF response to HU
on the four QOL outcomes – general health now (p <
0.001), general health perception (p < 0.001), 4-week
pain recall (p < 0.001) and social functioning (p = 0.007),
which was not statistically significant (p > 0.01) in a univariate model testing original treatment assignment only.
Baseline daily pain was an independent predictor of the
change in many of the QOL measures at all time points.
Stratification by average daily pain shows that high HbF
responders to HU whose average daily pain score was 5–9
achieved significant reduction in the tension scale compared to the placebo group and non-responders (p =
0.001, data not shown). However, HU showed no significant effect or trend of outcome difference on physical
functioning, physical role and ladder of life. There were
no significant time-by-treatment interactions.

Discussion
At entry, 33% of patients had HbF >0.5 g/dl. At two-years,
49% of HU-assigned patients had >0.5 g/dl HbF (mean
increase of 0.4 g/dl) compared to 23% of PL-assigned
patients (mean loss of 0.1 g/dl). Of the HU-assigned
patients defined as having the highest HbF response (the
upper half in %HbF change), 79% had >0.5 g/dl HbF at
two-years (mean increase of 0.8 g/dl Hb F), compared to
19% in low responders (zero mean change).
The PL and HU groups were comparable at baseline for all
scales of QOL. Over two years of treatment, no differences
between HU and PL in HQOL met the secondary endpoint critical value of p < 0.01 (Fig 3) However, HU-

Patients with chronic medical conditions (sickle cell anemia of any severity, Types I & II diabetes, congestive heart
failure, myocardial infarction, arthritis, chronic lung
problems, gastrointestinal disorders, back problems and
angina) have worse physical role and social functioning,
mental health, health perception, and/or body pain compared with patients with no chronic conditions [2,15,16].
Moreover, pain, by itself, has a negative impact on the
financial, emotional, legal, familial, physical, social, occupational and behavioral dimensions of life [4]. Alleviation of pain by different modalities has been shown to
improve the QOL for conditions other than sickle cell disease [17-20].
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Figure
Distribution
at
trial entry
3 of number of annual crises in 299 MSH patients
Distribution of number of annual crises in 299 MSH patients
at trial entry.
Hallmarks of SS include both recurrent episodes of acute
pain as well as chronic pain. Woods et al [15] used the SF36 to measure eight domains of health related to QOL in
143 adult SCD patients. Compared with patients with
other chronic conditions, patients with SCD had lower
(worse) scores than all other groups in the domains of
physical role functioning, social functioning, health perception and body pain. In the domain of physical functioning, they had very low scores comparable to the scores
of patients with congestive heart failure. Health and functional status scores for patients with SCD were similar to
or lower than scores for patients with diabetes, congestive
heart failure or back problems [[2,15-17] Table 1].
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moderate-severe sickle cell anemia, treated with hydroxyurea or placebo for two years, and classified according to 2year Hb-F response or placebo (short dashes). High responders (solid line) were above the 50th percentile of HbF change
from baseline to 2-years in the hydroxyurea group; low
responders (long dashes) were below the 50th percentile.
Mean quality of life measures and the standard error of the
mean are shown.

The impact of SCD on QOL is apparent in socioeconomic
data on 3,538 African-American patients enrolled in the
Cooperative Study of Sickle Cell Disease (CSSCD). That
study found that a higher percentage of patients were
unemployed and disabled compared to the US AfricanAmerican population [6]. Fuggle et al [21] found that
sickle cell pain resulted in over seven times increased risk
of absenteeism from school and was highly disruptive of
social and recreational activity of children with SCD.
However, Kater et al [22], found that children with SCD in
the Amsterdam area were compromised in the physical
and psychological well-being, but not in cognitive or
social aspects of QOL. Anie et al [23] reported that recurrent pain is not the only feature of SCD but other impairments in health-related quality of life are also important
features. McClish et al [24] found that patients with SCD
experience health-related quality of life that is worse than
in the general population and most similar to patients
undergoing hemodialysis. These studies [22-24], however, were not randomized, double-blind clinical trials,
which MSH was.
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Table 2: Multivariate generalized estimating equations (GEE) model to assess the effect of high HbF response on QOL. The effect of
independent variables (rows) on each outcome measure (columns) at 6, 12, 18 and 24 months during randomized treatment to
hydroxyurea or placebo is shown. The dependent variables are: SF-36 Health Status Survey variables (as a percent scores), Mood
Profile, Ladder of Life.

Independent Variables

High Response
Baseline QOL Value
Baseline Daily Pain 0–3, 4–6, 7–9
Baseline Fetal Hemoglobin <0. 5 vs > 0. 5
Baseline Annual Crisis Rate <6 vs ≥ 6

High Response
Baseline QOL Value
Baseline Daily Pain 0–3, 4–6, 7–9
Baseline Fetal Hemoglobin <0. 5 vs > 0. 5
Baseline Annual Crisis Rate <6 vs ≥ 6

quality of life Outcome Variables (each column is one model per outcome)
General
Physical
Social
RoleRole-Mental
Mental
EnergyHealth Now
Functioning
Functioning
Physical
Health
Fatigue
0.0008
<0.0001
<0.0001
NS
0.002

NS*
< 0.0001
NS
NS
NS

0.007
< 0.0001
<0.0001
NS
NS

NS
< 0.0001
<0.0001
NS
0.0005

NS
< 0.0001
0.008
NS
NS

NS
< 0.0001
0.002
NS
NS

NS
< 0.0001
0.002
NS
NS

Pain Recall
(4-week)

General Health
Perception

TensionAnxiety

DepressionDejection

Vigor

Fatigue

Ladder of Life

0.0006
< 0.0001
< 0.0001
NS
<0.0001

0.002
< 0.0001
NS
NS
0.003

NS
< 0.0001
0.001
NS
NS

NS
< 0.0001
<0.0001
NS
NS

NS
<0.0001
NS
NS
0.004

NS
<0.0001
0.0004
NS
NS

NS
< 0.0001
0.007
NS
0.008

* NS = p > .01

Treatment of SS patients with HU improves their clinical
and hematological characteristics [8,9,23,24]. The present
data show that hydroxyurea can also improve some measures of QOL including "general health now," general
health perception and pain recall. The effect was especially evident in patients with sustained HbF response to
HU. The strength of the favorable effect on social functioning, however, was not significant (p > 0.01).

The absolute scores by the ladder of life scale are better
than expected. This may reflect the optimism and positive
attitudes of subjects who enrolled in this clinical trial.
Subjects who consented to participate in the study may
have been eager to benefit from the possibility of
improvement that could be brought in by HU therapy;
they received regular attention and clinical center staff
support that may not be available to all patients with SCA.

Lack of demonstrable effect of HU relative to PL on certain
QOL measures in our patients (physical functioning,
physical role and ladder of life) may be the result of issues
inherent in the process of selection for the MSH of
patients with moderate-to-severe disease who were
already debilitated and had irreversible effects of their disease. Our patients had frequent acute pain episodes and
high levels of mean pain scores reported at baseline (Fig.
1A and 1B). Even though many experienced an average of
50% reduction in acute pain episodes [8,9], they still had
frequent acute pain episodes and high levels of chronic
pain. Patients with complications like avascular necrosis
may have irreversible limited range of motion of affected
joints and patients with previous strokes may have permanent neurological defects. In our study there was strong
evidence that these aspects of quality of life were influenced by the patients' quality of life, daily pain, and
annual crises rate before enrollment (Table 2). Earlier
treatment of individuals with SS before they have severe
consequences of their disease may be an area for future
investigation.

Even though the high and low HbF responder analysis is
post-hoc (i.e., based on 2-year HbF data after the QOL
data was collected), the HbF responses occurs within
weeks of HU initiation and is sustained through 2 years of
treatment. Our data indicate that the increase in HbF level
in subjects with SCD reduces the frequency of painful episodes [8,9] and now is shown to improve certain measures of HQOL. Because subjects in this study already had
moderate-to-severe SS, improvements in QOL with HU
treatment relative to PL were moderate and concentrated
among those patients with high HbF response to HU. A
question for further investigation is whether patients with
less severe disease, treated with HU before they develop
irreversible debilitating side effects, may benefit from prevention of loss of health status and quality of life.

Conclusion
The quality of life of patients with sickle cell anemia is
severely compromised similar to or even worse than
patients with other chronic diseases such as arthritis.
Patients who responded to hydroxyurea therapy had
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the MSH Investigators listed in references [8] and [9] for enrolling patients
in this study.
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